Stockwatch: Second-Quarter Earnings Highlight The Duracell Bunny PD-1 Inhibitor Race Winner
The Pandemic’s Impact On Oncology Drug Prescription Growth May Have Amplified Differences Between Similar Products
Executive Summary
After the differing second-quarter financial performances of Roche, AstraZeneca and Pfizer’s oncology franchises, the reports by Merck & Co and BMS should have helped define the effects of the pandemic on oncology businesses.